TY  - JOUR
AU  - Hughes, Walter
PY  - 2018
DA  - 2018/12/06
TI  - Reminiscence from Half a Century of Anti-<em>Pneumocystis</em> Drug Discovery and Development
JO  - OBM Genetics
SP  - 052
VL  - 02
IS  - 04
AB  - My experiences with the identification and development of the anti-Pneumocystis drugs trimethoprim-sulfamethoxazole, dapsone and atovaquone are recounted. Attention is drawn to certain often-overlooked aspects of these drugs, including their concomitant effects against infections other than Pneumocystis, matters of dosing and adverse effects. During the past four decades several million people worldwide received chemoprophylaxis and treatment with these drugs for Pneumocystis jirovecii pneumonia. The population of immunocompromised patients susceptible to this infection is expected to increase in the future and new drugs may be needed. Despite the discovery of many promising new anti-Pneumocystis drugs in the laboratory, none has received FDA approval for clinical use within the past 25 years. Opportunities for translational studies to advance these discoveries and others to clinical application are discussed.
SN  - 2577-5790
UR  - https://doi.org/10.21926/obm.genet.1804052
DO  - 10.21926/obm.genet.1804052
ID  - Hughes2018
ER  -